Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study
Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study Academic Background Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) are among the most common malignancies in children. Although the cure rate for newly diagnosed ALL and LL patients is relatively high, 10% to ...